Markets Featured

The Cancer Test America Canceled in 2010 Just Came Back

The American Cancer Society just reversed sixteen years of guidance and put routine PSA screening back on the calendar for tens of millions of men. The real catalyst is the federal panel that controls what insurers must cover - and its update is already in progress.

Alpha One

13 Nov 2026 • 6 min read

On Thursday morning, the American Cancer Society did something institutions of its size almost never do: it reversed itself. In new guidelines published in CA: A Cancer Journal for Clinicians, the ACS now recommends that average-risk American men aged 50 to 69 get a prostate-specific antigen (PSA) blood test every two years. Black men and men with a strong family history of prostate cancer should start yearly testing at 45.

For sixteen years, the official posture was the opposite. The ACS dropped routine PSA screening from its guidelines in 2010, leaving the decision to individual men and their doctors. The U.S. Preventive Services Task Force went further in 2012, recommending against the test outright for all ages, before softening to "it's your call" for men 55 to 69 in 2018. A generation of primary care physicians was trained to treat the PSA test as a trap: a blood test that found too many slow-growing tumors, triggered too many needless biopsies, and pushed too many men into surgeries and radiation that left them incontinent or impotent over cancers that would never have killed them.

That era ended today. And because roughly one in eight American men will be diagnosed with prostate cancer in his lifetime, the decision touches more households — and moves more money through the health care system — than almost any guideline change in recent memory.

What actually changed

The new ACS protocol, in plain terms:

Ages 50–69, average risk: PSA blood test every two years.
Age 45, high risk: yearly testing for Black men and men with a strong family history. Black men die of prostate cancer at disproportionate rates, and the guideline authors say earlier surveillance is aimed directly at catching their cancers before they reach advanced stages.
Age 70+: individualized decision; the benefit-harm balance gets murky. Screening should stop after 80, or in men not expected to live another 10 years.
The threshold moved. A PSA reading of 3.0 nanograms per milliliter or higher now counts as elevated for men 45 to 69. Most U.S. lab reports still flag 4.0 as the line. James Eastham, chief of urology at Memorial Sloan Kettering, told STAT the clarification should push primary care doctors to refer patients earlier.
The funnel got smarter. An elevated reading no longer sends a man straight to biopsy. The guidelines call for a second confirmatory PSA test, then an MRI and/or a biomarker test, before any needle comes out. That sequencing is the ACS's answer to the overdiagnosis problem that killed the test's reputation in the first place.

Why the reversal happened

Two things changed since 2010: the evidence and the toolkit.

The evidence: recent analyses — including a 2026 Cochrane review covered by STAT in May — found that PSA-based screening does reduce prostate cancer deaths for certain men. At the same time, the ACS's own statistics turned ominous. The U.S. prostate cancer death rate fell by roughly half between 1993 and 2023, but that decline has recently slowed — and the society attributes the stall, in part, to a rise in cancers being caught at advanced stages. Diagnoses climbed about 3% per year between 2014 and 2022. The ACS expects about 333,830 new U.S. cases and about 36,320 deaths in 2026, making prostate cancer the second-deadliest cancer in American men after lung. The uncomfortable arithmetic is that America stopped looking for the disease, and the disease started showing up later and deadlier.

The toolkit: in 2010, an elevated PSA led more or less directly to a biopsy, and a biopsy often led to treatment regardless of how indolent the tumor was. In 2026, there is an entire intermediate industry — multiparametric MRI, blood and urine biomarker panels, genomic classifiers — built to separate the cancers that kill from the cancers that don't. The new guidelines lean on that machinery explicitly, and they pair it with a strong push for active surveillance: finding more early-stage disease, the authors stress, "does not mean that you need to rush for therapies."

Briefings like this are free to read with a free AlphaBriefing membership. Join free →

Follow the funnel, follow the money

A screening guideline is a demand schedule. Every step of the new ACS pathway maps onto a commercial layer:

The blood draw. Tens of millions of men are in the 50-to-69 window, and the recommendation converts an optional conversation into a default every-two-years lab order. The PSA test itself is cheap and commoditized — which is exactly why the volume accrues to scale players: the national reference labs, led by Quest Diagnostics and Labcorp, and the hospital lab networks that process routine bloodwork.

The second look. The new protocol's buffer zone — confirmatory PSA, then MRI and/or biomarkers — is where the economics get interesting. Prostate MRI volume becomes a structural grower for imaging providers and for the equipment makers behind them. On the biomarker side, a crowded field of diagnostics firms has spent a decade building tests designed for precisely this slot: deciding which elevated PSA actually warrants a biopsy, and which biopsy-confirmed cancer actually warrants treatment. Notably, the ACS declined to pick winners — the guidelines recommend the category without endorsing any specific test, and the society says it intends to study which biomarkers best predict aggressive disease. That is a standards race now worth running.

The staging layer. More screening means more confirmed cancers, and modern prostate cancer staging increasingly runs through PSMA-targeted PET imaging — one of the fastest-growing corners of radiopharmaceuticals, with Lantheus and Telix the established commercial players in tracers and Novartis having built the flagship therapeutic franchise in PSMA radioligand therapy.

The treatment base. Even with active surveillance doing more work, a larger diagnosed population arithmetically expands the pool flowing toward robotic prostatectomy, radiation oncology, and the androgen-pathway drug franchises that dominate advanced disease. Earlier detection shifts the mix toward curable, lower-cost intervention — that is the public health point — but it widens the top of the funnel for everyone downstream.

The catch: the body that controls the money hasn't moved

Here is the detail that matters most for anyone modeling this: the American Cancer Society does not decide what insurers must cover. The U.S. Preventive Services Task Force does. Under the Affordable Care Act, only services with a USPSTF grade of A or B must be covered by private insurers with no cost-sharing — and PSA screening still carries the task force's 2018 grades: a C for men 55 to 69 (individualized decision) and a D for men 70 and up. Medicare covers an annual PSA test for men over 50 by statute, a carve-out dating to 2000, but for the commercially insured population the ACS has just recommended a test that federal rules do not yet require plans to make free.

That gap is temporary by design. The task force has formally announced that its prostate cancer recommendation is being updated, with the post-2025 evidence on the table. If the USPSTF follows the ACS to a B grade for men in their 50s and 60s, no-cost PSA screening becomes a legal mandate across commercial insurance — and the volume story above stops being discretionary. The USPSTF update, not today's announcement, is the event that flips the switch. Today's announcement tells you which way the wind is blowing while the committee deliberates.

The last time American medicine ran this experiment in reverse — un-recommending a cancer test and watching late-stage diagnoses drift upward for a decade — it took sixteen years to admit the correction. The institutions that move money on screening guidance now have their precedent, their evidence base, and their deadline pressure all pointing the same direction.

If this analysis was useful, this is what AlphaBriefing does every day — the biggest forces in health care, policy, and markets, connected to what they mean for your money. A free membership gets you access to every free article on AlphaBriefing.com; paid members get the investment frameworks, scenario pricing, and catalyst calendars behind the paywall.

Sign up free → — upgrade whenever it earns it.

A free membership gets you access to every free article at AlphaBriefing.com: Join AlphaBriefing

Get this level of intelligence every day. Subscribe to AlphaBriefing — free, member, and paid tiers available.

Sources & Further Reading

Disclaimer

AlphaBriefing is an independent intelligence publication. The content in this article is produced for informational and educational purposes only. Nothing published by AlphaBriefing constitutes financial, investment, legal, tax, or regulatory advice, nor should it be construed as a solicitation or recommendation to buy, sell, or hold any security, asset, or financial instrument.

All views expressed are those of the author at the time of writing and are subject to change without notice. Markets are volatile and unpredictable; past performance is not indicative of future results. Any investment involves risk, including the possible loss of principal.

AlphaBriefing and its principals, employees, or contributors may hold positions in securities or assets mentioned in this article. This should be considered a potential conflict of interest. No material relationship with any company referenced exists unless explicitly disclosed. Readers should conduct their own due diligence and consult qualified financial, legal, and tax advisors before making any investment decisions.

Information in this article is drawn from public sources believed to be reliable at the time of publication. AlphaBriefing makes no warranty, express or implied, as to the accuracy, completeness, or timeliness of any information herein. AlphaBriefing accepts no liability for any loss or damage arising from reliance on this content.